Testosterone Cypionate and Heart Health: What Long-Term Users Need to Know
Has the Cardiovascular Safety Question Been Answered?
For years, the relationship between Testosterone Cypionate and heart health was dominated by fear, conflicting studies, and regulatory caution. That changed in 2023. Hemi Pharma UK provides Janoshik-tested Testosterone Cypionate 200mg for UK users, and the cardiovascular evidence now available allows a much clearer conversation about what testosterone does and does not do to your heart, at both TRT and performance doses.
The answer depends entirely on the dose. At physiological replacement levels, testosterone therapy does not increase cardiovascular events and may improve several markers of cardiometabolic health. At supraphysiological bodybuilding doses, testosterone and stacked androgens cause measurable, dose-dependent cardiac changes that are potentially reversible but carry cumulative risk with prolonged use.
What Did the TRAVERSE Trial Prove?
The TRAVERSE trial is the single most important study ever conducted on Testosterone Cypionate and heart health. Published in the New England Journal of Medicine in 2023, it was a phase 4, multicentre, randomised, double-blind, placebo-controlled noninferiority trial. It enrolled 5,246 men aged 45 to 80 with preexisting cardiovascular disease or high cardiovascular risk, all with confirmed hypogonadism (two fasting testosterone readings below 300 ng/dL). Participants received either daily transdermal testosterone gel (dose-adjusted to maintain levels of 350 to 750 ng/dL) or placebo, with a mean follow-up of 3.19 years (Lincoff et al., NEJM 2023).
The primary outcome was the first occurrence of major adverse cardiovascular events (MACE): cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Testosterone therapy was noninferior to placebo. The hazard ratio was 0.81 (95% CI 0.67 to 0.98), meaning the testosterone group actually experienced fewer MACE events than the placebo group, although the trial was designed as noninferiority rather than superiority, so this cannot be interpreted as definitive proof of benefit.
What TRAVERSE Also Revealed
The trial was not entirely reassuring. The testosterone group had a higher incidence of nonfatal arrhythmias requiring intervention, including atrial fibrillation, and a higher rate of acute kidney injury and pulmonary embolism. A 2025 position statement from the European Expert Panel for Testosterone Research concluded that these findings should be contextualised within the overall favourable safety profile but warrant monitoring in at-risk populations (Zitzmann et al., Andrology 2025).
For users of injectable Testosterone Cypionate at TRT doses, the TRAVERSE data is broadly applicable. The testosterone gel used in the trial produces the same circulating hormone. The key takeaway: TRT does not increase heart attack or stroke risk in men with documented hypogonadism, even those with preexisting cardiovascular disease.
Does Low Testosterone Itself Damage the Heart?
Yes. This is the often-overlooked half of the Testosterone Cypionate and heart health equation. Low testosterone is not a neutral state. It is independently associated with increased cardiovascular mortality, adverse lipid profiles, insulin resistance, visceral adiposity, and endothelial dysfunction.
A 2024 study of 1,724 male patients undergoing coronary angiography found that lower serum total testosterone was significantly associated with more severe coronary artery disease as measured by the Gensini score, and with a higher incidence of myocardial infarction among those with confirmed coronary heart disease (cardiovascular and testosterone angiography study, 2024).
An 11-year observational registry tracking hypogonadal men found that the untreated group had a mortality rate almost double that of the testosterone-treated group (15.2% vs 7.8%), with 100% of deaths in the untreated group attributable to cardiovascular causes compared to 44% in the treated group. Leaving low testosterone untreated is not the safe option many assume it to be.
What Does Testosterone Do to Atherosclerosis?
One of the more nuanced questions about Testosterone Cypionate and heart health is whether testosterone accelerates arterial plaque formation. The evidence is mixed but predominantly reassuring at TRT doses.
A three-year randomised controlled trial (the TTrials Cardiovascular substudy) administered testosterone or placebo to 306 older men (mean age 67.6 years) with low or low-normal testosterone. After three years, there was no significant difference in carotid intima-media thickness progression (0.012 mm/year testosterone vs 0.010 mm/year placebo) and no difference in coronary artery calcium scores (mean difference of negative 10.8 Agatston units/year, p equals 0.54) (Basaria et al., JAMA 2015, reviewed in Farias 2021).
A separate 12-month study did find that testosterone treatment was associated with a greater increase in noncalcified coronary plaque volume compared to placebo (median increase from 204 to 232mm3 vs 317 to 325mm3). However, this study enrolled older men with mean age 71.2 years, 50.7% of whom already had severe atherosclerosis (Agatston score above 300) at baseline (Budoff et al., JAMA 2017). Whether this finding applies to younger men on TRT with healthier arteries is unclear.
The Androgen Society’s position paper on cardiovascular risk concluded that the overall evidence does not support an association between testosterone therapy and atherosclerosis progression in men with documented hypogonadism (Androgen Society, Mayo Clin Proc 2024).
What Happens to the Heart at Supraphysiological Doses?
This is where the conversation shifts. For men using Testosterone Cypionate at performance doses (300mg per week and above), or stacking with compounds like Nandrolone, Trenbolone, or oral steroids, the cardiac effects are measurable and dose-dependent.
The HAARLEM Study: Prospective Data on Steroid Users
The HAARLEM study is the most important prospective cardiac study in recreational steroid users. Researchers at Spaarne Gasthuis Hospital in the Netherlands recruited 31 men who were about to start a steroid cycle and performed comprehensive 3D echocardiography before, at the end of the cycle (median 16 weeks), and after a recovery period (median 8 months). Key findings (Smit et al., Front Reprod Health 2021):
Left ventricular ejection fraction (LVEF) declined by 4.9% during the cycle (p less than 0.001). The E/A ratio (a marker of diastolic function and ventricular stiffness) declined by 0.45 (p less than 0.001). Left ventricular mass increased by 28.3g (p less than 0.001), and there was a positive correlation between average weekly androgen dose and LV mass increase. Left atrial volume increased by 9.2ml (p equals 0.004).
Crucially, all parameters returned to baseline after the recovery period. The researchers concluded that AAS-induced cardiac changes are reversible when cycles are followed by adequate recovery time. However, they hypothesised that cumulative damage may occur when recovery time between cycles is too short or when androgens are used continuously at supraphysiological doses.
Cross-Sectional Evidence
A 2023 cross-sectional study of 92 males (48 AAS users, 26 non-user athletes, 18 sedentary controls) found that steroid users had significantly increased left ventricular and left atrial remodelling compared to both control groups (p less than 0.001). Twenty-eight steroid users (58.3%) had cardiac remodelling on echocardiography (JSAMS 2023).
How Does Haematocrit Affect Cardiovascular Risk?
Testosterone stimulates erythropoiesis. Elevated haematocrit (above 54%) increases blood viscosity, raising blood pressure and the risk of thromboembolic events including deep vein thrombosis, pulmonary embolism, and stroke. This is the most directly actionable cardiovascular risk for any user of Testosterone Cypionate.
The TRAVERSE trial confirmed a higher incidence of pulmonary embolism in the testosterone group. Haematocrit monitoring is therefore non-negotiable. The British Society for Sexual Medicine recommends checking haematocrit at baseline, three months, six months, twelve months, and annually thereafter. If haematocrit exceeds 54%, the dose should be reduced or therapeutic phlebotomy considered.
Splitting your weekly Testosterone Cypionate dose into two or more injections (for example, 100mg on Monday and 100mg on Thursday instead of 200mg once weekly) reduces peak testosterone levels and attenuates the erythropoietic stimulus, which can help manage haematocrit without reducing total weekly dose.
What About Lipid Profiles?
Testosterone at TRT doses has a modest effect on lipids. HDL cholesterol typically decreases by 5 to 15%, while LDL may remain unchanged or decrease slightly. A 2025 systematic review of TRT’s cardiovascular effects across multiple trials noted that the lipid changes were generally small and not clinically significant in most studies, particularly when testosterone was administered at physiological replacement doses (cardiovascular effects systematic review, 2025).
At supraphysiological doses, the effect is more pronounced. Oral steroids like Winstrol and Anavar (Oxandrolone) have a particularly aggressive impact on HDL, sometimes reducing it by 50% or more. Injectable testosterone at moderate performance doses (300 to 500mg per week) causes a lesser but still meaningful HDL suppression. Stacking with Trenbolone or Nandrolone compounds the effect.
For heart health, maintaining HDL above 1.0 mmol/L is a practical target. If lipid panels show significant HDL suppression, adding cardiovascular exercise (which independently raises HDL), supplementing with omega-3 fatty acids, and considering dose reduction are all evidence-based strategies.
How to Protect Your Heart on Testosterone Cypionate
Whether you use Testosterone Cypionate for TRT or performance, cardiovascular protection comes down to monitoring and modifiable risk factors.
Monitor haematocrit at every blood draw. Keep it below 54%. If it rises above this, reduce dose, increase injection frequency, or donate blood. Monitor blood pressure. Buy a home monitor and check weekly. Target below 130/80 mmHg. If consistently elevated, address with cardiovascular exercise, sodium restriction, weight management, or medication. Monitor lipids every six months. Watch HDL in particular. If it drops below 1.0 mmol/L, review your protocol. Perform cardiovascular exercise regularly. A minimum of 150 minutes per week of moderate-intensity cardio (walking, cycling, swimming) is the single most protective behaviour for heart health on testosterone. Limit oral steroids. 17-alpha-alkylated compounds (Anavar, Winstrol) stress the liver and aggressively suppress HDL. Use them sparingly and for limited durations. Allow recovery between cycles. The HAARLEM study showed cardiac changes are reversible with adequate time off. Continuous supraphysiological use without recovery periods is the highest-risk pattern. Manage oestradiol. Both excessively high and excessively low oestradiol are associated with adverse cardiovascular markers. Use Anastrozole judiciously rather than aggressively. Control body weight. Excessive body mass, whether from muscle or fat, increases cardiac workload. Bodybuilders above 110kg carry significantly higher cardiovascular strain regardless of body composition.
Does Testosterone Cypionate Affect Heart Rhythm?
The TRAVERSE trial flagged a higher rate of atrial fibrillation in the testosterone group. This finding, while not part of the primary MACE endpoint, is clinically relevant. Atrial fibrillation increases stroke risk fivefold and is more common in men with elevated haematocrit and blood pressure, both of which testosterone can influence.
If you experience palpitations, an irregular heartbeat, unexplained shortness of breath, or dizziness while on Testosterone Cypionate, seek medical assessment. An ECG and, if indicated, a Holter monitor can detect rhythm abnormalities. Men with a family history of atrial fibrillation or existing heart rhythm issues should discuss this with their GP before starting TRT.
What Do the Experts Now Recommend?
The 2025 European Expert Panel for Testosterone Research position statement, authored by leading endocrinologists including Zitzmann, Corona, and Jones, concluded that TRT is cardiovascularly safe when used as indicated in men with documented hypogonadism. They recommended that TRT should not be withheld from hypogonadal men on cardiovascular grounds alone, but that monitoring of haematocrit, blood pressure, and lipids should be routine. They also stated that the findings from TRAVERSE align with prior meta-analyses that found no increased cardiovascular risk from testosterone therapy.
For UK users of Testosterone Cypionate at TRT doses, this represents the strongest evidence base to date. The heart risk is not in the testosterone. It is in the failure to monitor.
Frequently Asked Questions
Does Testosterone Cypionate cause heart attacks?
At TRT doses, no. The TRAVERSE trial (5,246 men, 3.19 years follow-up) found no increased risk of major cardiovascular events with testosterone therapy compared to placebo, even in men with preexisting cardiovascular disease. The hazard ratio was 0.81, numerically favouring testosterone.
Is Testosterone Cypionate safe for the heart long-term?
At physiological replacement doses with proper monitoring, the evidence supports long-term cardiovascular safety. Observational data extending beyond five years shows sustained cardiometabolic benefits. At supraphysiological doses, cardiac remodelling occurs but is reversible with adequate recovery time.
What is the biggest heart risk from Testosterone Cypionate?
Elevated haematocrit leading to increased blood viscosity and thromboembolic events. The TRAVERSE trial confirmed higher rates of pulmonary embolism in the testosterone group. Regular haematocrit monitoring and keeping levels below 54% is the single most important cardiovascular precaution.
Does testosterone cause atrial fibrillation?
The TRAVERSE trial found a higher incidence of nonfatal arrhythmias including atrial fibrillation in the testosterone group. The clinical significance is debated, but men with existing rhythm disorders or a family history of atrial fibrillation should discuss this with their doctor before starting TRT.
Do bodybuilding doses of testosterone damage the heart?
Yes. The HAARLEM study found that a median 16-week steroid cycle caused left ventricular ejection fraction to decline by 4.9%, left ventricular mass to increase by 28.3g, and diastolic function to worsen. All changes reversed after a median 8-month recovery period, but cumulative damage may occur with insufficient recovery time.
How often should I check my cardiovascular markers on Testosterone Cypionate?
Haematocrit, blood pressure, and lipid profile should be checked at baseline, three months, six months, twelve months, and annually thereafter. Home blood pressure monitoring weekly is recommended. An ECG at baseline is prudent for men over 40 or those with cardiovascular risk factors.